PharmEco Group of Companies

Search

RU | EN

BioJet – EN
  • About
    • General information
    • Administration
    • Pharmacovigilance
    • Business ethics
  • Production
  • Our products
  • News
  • Contacts

Mishustin: 90% of Essential Medicines Should Be Produced in Russia

According to the Prime Minister, this goal will be pursued as part of the national project “New Health Preservation Technologies.”

The share of domestically produced medicines from the list of essential and vital drugs (EVDL) in Russia should increase to 90% by 2030, Russian Prime Minister Mikhail Mishustin announced.

He noted that this effort will be conducted within the framework of the national project “New Health Preservation Technologies.”

“Activities under the national project ‘New Health Preservation Technologies’ will help expand the use of biomedical technologies, regenerative medicine methods, and improve access for citizens to advanced approaches in prevention and treatment. The share of domestically produced essential and vital medicines should increase to 90%,” said the Prime Minister while addressing the National Projects Council.

In April, during a report on the government’s work in 2023, Mishustin stated that the current share of domestically produced medicines from the EVDL list stands at 80%.

Source: TASS, December 5, 2024

Current news

  • February 5, 2026

    Alikhanov: At Least 10 Pharmaceutical Manufacturing Facilities to Be Built in Russia by 2030

    By 2030, Russia plans to build at least 10 new pharmaceutical manufacturing facilities, Russian Minister…

  • February 5, 2026

    Ministry of Industry and Trade: The Share of Domestic Medicines in Russia Has Exceeded 60%

    The share of domestically produced medicines in Russia stands at 63%, and exceeds 80% in…

  • February 5, 2026

    Special Procedure for the Sale of Foreign Medicines Extended Until the End of 2027

    The special procedure for the sale in Russia of registered foreign medicinal products will remain…

  • February 5, 2026

    A Drug for Hepatitis B Therapy Developed in Russia

    Russian scientists have developed a drug for the treatment of hepatitis B based on CRISPR/Cas9…

  • February 5, 2026

    Methodological Guidelines Approved for Assessing Technological Processes in Pharmaceutical Manufacturing to Implement Government Resolution No. 719

    Starting July 1, 2026, Government Resolution of the Russian Federation No. 1392 dated September 10,…

LLC “BioJet”. all rights reserved

  • Legal information